Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 2:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, Oxytocin nasal spray, Placebo Oxycodone, Placebo oxytocin, OxyCODONE 2.5 mg Oral Tablet
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Sprix for Postoperative Pain Control Following Gynecologic Surgery

NCT04444830
Conditions
Post Operative Pain Control, Narcotic Use, Pelvic Organ Prolapse, Urinary Incontinence , Stress, Surgery
Interventions
Sprix
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Recreational Drug Use
Interventions
PF614, Oxycodone, Placebo
Drug · Other
Lead sponsor
Ensysce Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Pain
Interventions
OxyCODONE 5 mg Oral Tablet, OxyCODONE 2.5 mg Oral Tablet, Placebo oxyCODONE Oral Tablet, Oxytocin Nasal Spray (48 IU), Placebo Oxytocin Nasal Spray
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

NCT06453265
Conditions
Abuse, Drug
Interventions
Cebranopadol- 600 ug, Cebranopadol- 800ug, Cebranopadol- 1000ug, Treatment A:, Treatment B, Treatment C, Qualification
Drug
Lead sponsor
Tris Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Accepts healthy volunteers Results available

Aprepitant Effects on Oxycodone Response

NCT00999544
Conditions
Narcotic Abuse
Interventions
Aprepitant 0mg, Aprepitant 40mg, Aprepitant 200mg, Oxycodone 0mg, p.o., Oxycodone 20mg, p.o., Oxycodone 40mg, p.o., Oxycodone 0mg, IN, Oxycodone 15mg, IN, Oxycodone 30mg, IN
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Lexington, Kentucky
Terminated Phase 2 Interventional Results available

Evaluation of Doxazosin to Alter the Abuse of Oxycodone

NCT03415581
Conditions
Opioid-use Disorder
Interventions
Intranasal Oxycodone, Cue Session
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 59 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Manhattan, New York